Jones Financial Companies
GALT icon

Jones Financial Companies’s Galectin Therapeutics GALT Stock Holding History

Jones Financial Companies’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1K Buy
5,423
+4,423
+442% +$11.5K ﹤0.01% 3377
2026
Q1 		$2.68K Buy
+1,000
New +$3.04K ﹤0.01% 4067

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jones Financial Companies's GALT Position: Q2 2026 in Review

Jones Financial Companies increased its Galectin Therapeutics (GALT) stake by 442% in Q2 2026, buying an estimated $11.5K and bringing the position to 5,423 shares worth $27.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3377.

Jones Financial Companies first reported a position in GALT in Q1 2026 and has held it in 2 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Jones Financial Companies held 5,423 shares of Galectin Therapeutics worth $27.1K as of Q2 2026.
  • Jones Financial Companies bought 4,423 Galectin Therapeutics shares in Q2 2026, an estimated $11.5K.
  • Galectin Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3377 holding.
  • Jones Financial Companies first reported a position in Galectin Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.